Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molgramostim Inhalation for COVID-19 Pneumonia (GI-COVID)
NCT04569877Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of molgramostim in COVID-19 pneumonia, sponsored by Justus Liebig University Giessen. Started Sep 2020; status: completed.
02
Drugs
molgramostim
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04569877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569877.